Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

Institut Paoli-Calmettes235 enrolled

Overview

The objective of this study was to evaluate the outcome of patients affected with different subtypes of metastatic breast cancer following treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation.

Study Type

OBSERVATIONAL

Enrollment

235

Conditions

Breast Neoplasms

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age\>18 years * Metastatic breast Cancer * Treatment with high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation between 2003 and 2012 Exclusion Criteria: * Lack of follow-up data

Locations (1)

Institut Paoli-Calmettes

Marseille, France

Outcomes

Primary Outcomes

Overall Survival according to Immunohistochemical subtypes .

Time frame: 8 years

Secondary Outcomes

Progression free Survival according to Immunohistochemical subtypes .

Time frame: 8 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.